Allergan Under Investigation By Oregon For Deceptive Promotions
This article was originally published in The Pink Sheet Daily
Executive Summary
State effort is focused on one unnamed drug but may expand; the company is already facing a federal inquiry about off-label promotion of Botox for headache treatment.
You may also be interested in...
FDA Looks To States For Warning Letter Help; Policy Change Boosts Enforcement
The pieces are in place for states to contribute evidence or data to FDA that can be used to build compliance actions
FDA Looks To States For Warning Letter Help; Policy Change Boosts Enforcement
The pieces are in place for states to contribute evidence or data to FDA that can be used to build compliance actions
Beauty Is A Pain: FDA Cites Latisse Web Site For Implying Drug Is A Cosmetic
Allergan's consumer Web site for its eyelash growth drug, Latisse,certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic